Investegate |GNT Pharma Co., Ltd Announcements | GNT Pharma Co., Ltd: GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)

Investegate announcements from GNT Pharma Co., Ltd, GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)

Related Keywords

China ,Seoul ,Soult Ukpyolsi ,South Korea ,Chinese ,Korea ,Byoung Joo Gwag ,Dennisw Choi ,Byung Chul Kim ,Chang Geun Kim ,Apeloa Pharmaceutical Of Hengdian Group ,National Institutes Of Health Stroke Scale ,Korea Ministry Of Food ,Seoul Asan Medical Center ,Phd Us Office ,Pharma Inc ,Provides Update ,Two Phase ,Acute Ischemic Stroke Patients Treated ,Endovascular Thrombectomy ,Ischemic Stroke ,Reperfusion Damage ,Cerebral Infarction ,Rankin Scale ,Stony Brook Medicine ,National Institutes ,Health Stroke Scale ,Apeloa Pharmaceutical ,Hengdian Group ,Korea Ministry ,Drug Safety ,Investigational New Drug Application ,Seoul Asan Medical ,Chan Park ,Geun Kim ,Chul Kim ,Public Relations Director ,Investegate Announcements ,Investegate Company Announcements ,Nt Pharma Co ,Td ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,